Stem definition | Drug id | CAS RN |
---|---|---|
histamine-H2-receptor antagonists, cimetidine derivatives | 645 | 51481-61-9 |
Dose | Unit | Route |
---|---|---|
0.80 | g | O |
0.80 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 6.20 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 62 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 158.51 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 60 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 1.20 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 8.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.78 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 2.20 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 16, 1977 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Urine abnormality | 141.13 | 13.18 | 56 | 13833 | 6182 | 50585053 |
Urine leukocyte esterase positive | 121.71 | 13.18 | 41 | 13848 | 2842 | 50588393 |
Body tinea | 111.63 | 13.18 | 32 | 13857 | 1295 | 50589940 |
Inhibitory drug interaction | 95.22 | 13.18 | 32 | 13857 | 2201 | 50589034 |
Infection susceptibility increased | 90.64 | 13.18 | 32 | 13857 | 2552 | 50588683 |
Lymphocyte count decreased | 80.81 | 13.18 | 63 | 13826 | 26244 | 50564991 |
Glucose tolerance impaired | 72.61 | 13.18 | 33 | 13856 | 5085 | 50586150 |
Impaired quality of life | 67.32 | 13.18 | 33 | 13856 | 6023 | 50585212 |
Culture urine positive | 64.43 | 13.18 | 27 | 13862 | 3424 | 50587811 |
Urine ketone body present | 63.63 | 13.18 | 24 | 13865 | 2309 | 50588926 |
Purpura | 57.17 | 13.18 | 35 | 13854 | 9876 | 50581359 |
Chronic kidney disease | 56.70 | 13.18 | 62 | 13827 | 39709 | 50551526 |
Hyperlipidaemia | 56.13 | 13.18 | 43 | 13846 | 17447 | 50573788 |
Blood urine present | 55.95 | 13.18 | 38 | 13851 | 12795 | 50578440 |
Poor quality sleep | 51.40 | 13.18 | 40 | 13849 | 16606 | 50574629 |
Bone density decreased | 51.17 | 13.18 | 34 | 13855 | 11041 | 50580194 |
Anaphylactoid reaction | 48.44 | 13.18 | 22 | 13867 | 3384 | 50587851 |
Drug intolerance | 48.26 | 13.18 | 3 | 13886 | 219101 | 50372134 |
Erythema | 43.17 | 13.18 | 112 | 13777 | 146302 | 50444933 |
Impaired work ability | 40.43 | 13.18 | 32 | 13857 | 13608 | 50577627 |
Neutrophil count increased | 37.22 | 13.18 | 31 | 13858 | 14164 | 50577071 |
Joint swelling | 36.51 | 13.18 | 11 | 13878 | 245275 | 50345960 |
Torsade de pointes | 35.59 | 13.18 | 28 | 13861 | 11807 | 50579428 |
Oral herpes | 34.31 | 13.18 | 35 | 13854 | 20690 | 50570545 |
Rheumatoid arthritis | 34.17 | 13.18 | 7 | 13882 | 202543 | 50388692 |
Skin disorder | 31.73 | 13.18 | 36 | 13853 | 23994 | 50567241 |
Hypertension | 31.54 | 13.18 | 128 | 13761 | 211075 | 50380160 |
Drug ineffective | 31.20 | 13.18 | 118 | 13771 | 819215 | 49772020 |
Bacterial test positive | 30.66 | 13.18 | 18 | 13871 | 4705 | 50586530 |
Band sensation | 29.86 | 13.18 | 10 | 13879 | 680 | 50590555 |
Keratitis | 28.99 | 13.18 | 14 | 13875 | 2471 | 50588764 |
Tri-iodothyronine free decreased | 28.44 | 13.18 | 8 | 13881 | 302 | 50590933 |
Creatinine urine decreased | 27.92 | 13.18 | 7 | 13882 | 168 | 50591067 |
Infusion site scar | 27.80 | 13.18 | 8 | 13881 | 328 | 50590907 |
Red cell distribution width increased | 27.36 | 13.18 | 21 | 13868 | 8538 | 50582697 |
Specific gravity urine decreased | 25.98 | 13.18 | 9 | 13880 | 678 | 50590557 |
Urticaria | 25.60 | 13.18 | 86 | 13803 | 129475 | 50461760 |
Cataract | 23.96 | 13.18 | 45 | 13844 | 47255 | 50543980 |
Infusion site discomfort | 23.83 | 13.18 | 9 | 13880 | 869 | 50590366 |
Anxiety | 23.67 | 13.18 | 104 | 13785 | 177502 | 50413733 |
Product use issue | 23.53 | 13.18 | 6 | 13883 | 149469 | 50441766 |
Electrocardiogram T wave amplitude decreased | 23.20 | 13.18 | 7 | 13882 | 339 | 50590896 |
Insomnia | 23.00 | 13.18 | 102 | 13787 | 174763 | 50416472 |
Product dose omission issue | 22.76 | 13.18 | 11 | 13878 | 183827 | 50407408 |
Cellulitis | 22.75 | 13.18 | 56 | 13833 | 70742 | 50520493 |
Circulatory collapse | 21.52 | 13.18 | 27 | 13862 | 19973 | 50571262 |
Red blood cell count decreased | 20.75 | 13.18 | 35 | 13854 | 33800 | 50557435 |
Basophil count increased | 20.68 | 13.18 | 8 | 13881 | 824 | 50590411 |
Alanine aminotransferase increased | 20.50 | 13.18 | 62 | 13827 | 88297 | 50502938 |
Therapeutic product effect decreased | 20.41 | 13.18 | 6 | 13883 | 136044 | 50455191 |
Death | 19.93 | 13.18 | 155 | 13734 | 325224 | 50266011 |
Blood thyroid stimulating hormone increased | 19.59 | 13.18 | 15 | 13874 | 6077 | 50585158 |
Peripheral swelling | 19.15 | 13.18 | 17 | 13872 | 205919 | 50385316 |
Red blood cells urine positive | 19.14 | 13.18 | 11 | 13878 | 2764 | 50588471 |
Protein urine present | 18.98 | 13.18 | 14 | 13875 | 5363 | 50585872 |
Food interaction | 18.81 | 13.18 | 7 | 13882 | 649 | 50590586 |
Arthropathy | 18.71 | 13.18 | 10 | 13879 | 157896 | 50433339 |
Palmar-plantar erythrodysaesthesia syndrome | 18.31 | 13.18 | 25 | 13864 | 20073 | 50571162 |
Contraindicated product administered | 18.30 | 13.18 | 9 | 13880 | 148949 | 50442286 |
Chromaturia | 17.82 | 13.18 | 21 | 13868 | 14569 | 50576666 |
White blood cell count decreased | 17.60 | 13.18 | 71 | 13818 | 116651 | 50474584 |
C-reactive protein abnormal | 17.36 | 13.18 | 29 | 13860 | 27780 | 50563455 |
Wound | 17.13 | 13.18 | 4 | 13885 | 105790 | 50485445 |
Infusion site rash | 17.00 | 13.18 | 8 | 13881 | 1334 | 50589901 |
Urobilinogen urine increased | 16.76 | 13.18 | 5 | 13884 | 233 | 50591002 |
Systemic lupus erythematosus | 16.52 | 13.18 | 9 | 13880 | 140613 | 50450622 |
Infusion site warmth | 16.49 | 13.18 | 8 | 13881 | 1426 | 50589809 |
Flushing | 16.47 | 13.18 | 48 | 13841 | 66967 | 50524268 |
Nitrite urine present | 16.46 | 13.18 | 7 | 13882 | 920 | 50590315 |
Pancreatitis acute | 16.45 | 13.18 | 26 | 13863 | 23786 | 50567449 |
Maternal exposure during pregnancy | 16.34 | 13.18 | 12 | 13877 | 159766 | 50431469 |
Thyroid cyst | 16.01 | 13.18 | 6 | 13883 | 567 | 50590668 |
Feeling hot | 15.90 | 13.18 | 34 | 13855 | 39168 | 50552067 |
Red cell distribution width decreased | 15.28 | 13.18 | 7 | 13882 | 1098 | 50590137 |
Glucose urine present | 14.93 | 13.18 | 6 | 13883 | 684 | 50590551 |
Drug exposure before pregnancy | 14.61 | 13.18 | 6 | 13883 | 723 | 50590512 |
Immune thrombocytopenia | 14.51 | 13.18 | 15 | 13874 | 9002 | 50582233 |
Monocyte count decreased | 14.42 | 13.18 | 8 | 13881 | 1878 | 50589357 |
pH urine increased | 14.35 | 13.18 | 5 | 13884 | 383 | 50590852 |
Abdominal discomfort | 13.50 | 13.18 | 27 | 13862 | 231614 | 50359621 |
Ventricular tachycardia | 13.40 | 13.18 | 19 | 13870 | 15802 | 50575433 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Chronic kidney disease | 33.78 | 16.02 | 38 | 5572 | 36378 | 29532539 |
Renal injury | 19.75 | 16.02 | 16 | 5594 | 10186 | 29558731 |
Palmar-plantar erythrodysaesthesia syndrome | 18.32 | 16.02 | 18 | 5592 | 14741 | 29554176 |
Peptic ulcer | 18.02 | 16.02 | 9 | 5601 | 2476 | 29566441 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Urine abnormality | 150.32 | 13.17 | 60 | 16255 | 7302 | 64475115 |
Urine leukocyte esterase positive | 118.31 | 13.17 | 41 | 16274 | 3362 | 64479055 |
Body tinea | 110.46 | 13.17 | 31 | 16284 | 1262 | 64481155 |
Lymphocyte count decreased | 88.37 | 13.17 | 77 | 16238 | 40622 | 64441795 |
Infection susceptibility increased | 87.70 | 13.17 | 31 | 16284 | 2695 | 64479722 |
Inhibitory drug interaction | 86.18 | 13.17 | 33 | 16282 | 3594 | 64478823 |
Urine ketone body present | 71.16 | 13.17 | 28 | 16287 | 3279 | 64479138 |
Glucose tolerance impaired | 64.93 | 13.17 | 32 | 16283 | 6411 | 64476006 |
Impaired quality of life | 64.80 | 13.17 | 32 | 16283 | 6439 | 64475978 |
Culture urine positive | 61.74 | 13.17 | 27 | 16288 | 4124 | 64478293 |
Bone density decreased | 54.47 | 13.17 | 33 | 16282 | 9919 | 64472498 |
Poor quality sleep | 51.83 | 13.17 | 41 | 16274 | 18910 | 64463507 |
Hyperlipidaemia | 50.93 | 13.17 | 44 | 16271 | 22932 | 64459485 |
Blood urine present | 46.59 | 13.17 | 38 | 16277 | 18302 | 64464115 |
Purpura | 46.50 | 13.17 | 37 | 16278 | 17209 | 64465208 |
Erythema | 44.91 | 13.17 | 126 | 16189 | 186944 | 64295473 |
Anaphylactoid reaction | 43.23 | 13.17 | 22 | 16293 | 4716 | 64477701 |
Hypertension | 41.58 | 13.17 | 152 | 16163 | 259109 | 64223308 |
Torsade de pointes | 35.97 | 13.17 | 32 | 16283 | 17331 | 64465086 |
Impaired work ability | 35.47 | 13.17 | 30 | 16285 | 15189 | 64467228 |
Red cell distribution width increased | 34.45 | 13.17 | 27 | 16288 | 12282 | 64470135 |
Oral herpes | 32.93 | 13.17 | 34 | 16281 | 22118 | 64460299 |
Urticaria | 31.27 | 13.17 | 95 | 16220 | 147222 | 64335195 |
Palmar-plantar erythrodysaesthesia syndrome | 30.42 | 13.17 | 37 | 16278 | 28782 | 64453635 |
Infusion site scar | 30.33 | 13.17 | 8 | 16307 | 257 | 64482160 |
Keratitis | 29.44 | 13.17 | 15 | 16300 | 3222 | 64479195 |
Skin disorder | 28.35 | 13.17 | 35 | 16280 | 27645 | 64454772 |
Tri-iodothyronine free decreased | 27.88 | 13.17 | 8 | 16307 | 353 | 64482064 |
Chronic kidney disease | 27.31 | 13.17 | 51 | 16264 | 57868 | 64424549 |
Flushing | 27.29 | 13.17 | 61 | 16254 | 78587 | 64403830 |
Red blood cell count decreased | 27.18 | 13.17 | 46 | 16269 | 48340 | 64434077 |
Band sensation | 26.94 | 13.17 | 9 | 16306 | 660 | 64481757 |
Bacterial test positive | 26.26 | 13.17 | 18 | 16297 | 6672 | 64475745 |
Alanine aminotransferase increased | 26.15 | 13.17 | 86 | 16229 | 138945 | 64343472 |
Joint swelling | 25.94 | 13.17 | 11 | 16304 | 215371 | 64267046 |
Infusion site discomfort | 25.74 | 13.17 | 9 | 16306 | 757 | 64481660 |
Specific gravity urine decreased | 25.55 | 13.17 | 9 | 16306 | 774 | 64481643 |
Off label use | 25.49 | 13.17 | 79 | 16236 | 632727 | 63849690 |
Insomnia | 25.23 | 13.17 | 108 | 16207 | 197728 | 64284689 |
Cataract | 22.76 | 13.17 | 44 | 16271 | 51218 | 64431199 |
Monocyte count decreased | 22.44 | 13.17 | 12 | 16303 | 2845 | 64479572 |
Peptic ulcer | 22.41 | 13.17 | 15 | 16300 | 5348 | 64477069 |
Creatinine urine decreased | 21.98 | 13.17 | 6 | 16309 | 220 | 64482197 |
Secondary adrenocortical insufficiency | 21.72 | 13.17 | 11 | 16304 | 2334 | 64480083 |
Drug ineffective | 21.43 | 13.17 | 125 | 16190 | 840122 | 63642295 |
Ventricular tachycardia | 21.16 | 13.17 | 34 | 16281 | 34231 | 64448186 |
Basophil count increased | 21.12 | 13.17 | 9 | 16306 | 1291 | 64481126 |
Contusion | 20.98 | 13.17 | 70 | 16245 | 113895 | 64368522 |
Neutrophil count increased | 19.85 | 13.17 | 28 | 16287 | 25146 | 64457271 |
Infusion site warmth | 19.35 | 13.17 | 8 | 16307 | 1064 | 64481353 |
White blood cell count decreased | 19.22 | 13.17 | 85 | 16230 | 157752 | 64324665 |
Red cell distribution width decreased | 19.20 | 13.17 | 8 | 16307 | 1085 | 64481332 |
Dyspepsia | 19.14 | 13.17 | 54 | 16261 | 80258 | 64402159 |
Infusion site rash | 19.11 | 13.17 | 8 | 16307 | 1098 | 64481319 |
Rheumatoid arthritis | 18.82 | 13.17 | 9 | 16306 | 164285 | 64318132 |
Mean cell haemoglobin increased | 18.51 | 13.17 | 11 | 16304 | 3191 | 64479226 |
Haematocrit increased | 18.06 | 13.17 | 11 | 16304 | 3334 | 64479083 |
Blood thyroid stimulating hormone increased | 17.65 | 13.17 | 15 | 16300 | 7639 | 64474778 |
Protein urine present | 17.55 | 13.17 | 16 | 16299 | 8940 | 64473477 |
Anxiety | 17.49 | 13.17 | 99 | 16216 | 202550 | 64279867 |
Drug exposure before pregnancy | 17.34 | 13.17 | 6 | 16309 | 489 | 64481928 |
Therapeutic product effect decreased | 17.25 | 13.17 | 4 | 16311 | 115347 | 64367070 |
Gastrooesophageal reflux disease | 17.05 | 13.17 | 53 | 16262 | 83090 | 64399327 |
Therapeutic product effect incomplete | 16.69 | 13.17 | 3 | 16312 | 103479 | 64378938 |
Leukocyturia | 16.58 | 13.17 | 8 | 16307 | 1530 | 64480887 |
Electrocardiogram T wave amplitude decreased | 16.57 | 13.17 | 6 | 16309 | 559 | 64481858 |
Nitrite urine present | 16.03 | 13.17 | 7 | 16308 | 1065 | 64481352 |
Peripheral swelling | 15.54 | 13.17 | 18 | 16297 | 209135 | 64273282 |
C-reactive protein abnormal | 15.50 | 13.17 | 27 | 16288 | 29020 | 64453397 |
Product dose omission issue | 15.30 | 13.17 | 16 | 16299 | 194731 | 64287686 |
Infusion site pruritus | 15.19 | 13.17 | 9 | 16306 | 2597 | 64479820 |
Eosinophil count increased | 14.70 | 13.17 | 18 | 16297 | 14094 | 64468323 |
Thyroid cyst | 14.69 | 13.17 | 5 | 16310 | 388 | 64482029 |
Blood alkaline phosphatase increased | 14.56 | 13.17 | 39 | 16276 | 56240 | 64426177 |
pH urine increased | 14.20 | 13.17 | 5 | 16310 | 429 | 64481988 |
Aspartate aminotransferase increased | 14.19 | 13.17 | 64 | 16251 | 119724 | 64362693 |
Food interaction | 13.94 | 13.17 | 7 | 16308 | 1459 | 64480958 |
Duodenal ulcer haemorrhage | 13.78 | 13.17 | 12 | 16303 | 6313 | 64476104 |
Cellulitis | 13.39 | 13.17 | 53 | 16262 | 93604 | 64388813 |
Product use in unapproved indication | 13.33 | 13.17 | 15 | 16300 | 176603 | 64305814 |
White blood cells urine positive | 13.32 | 13.17 | 11 | 16304 | 5387 | 64477030 |
None
Source | Code | Description |
---|---|---|
ATC | A02BA01 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) H2-receptor antagonists |
ATC | A02BA51 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) H2-receptor antagonists |
FDA MoA | N0000000151 | Histamine H2 Receptor Antagonists |
CHEBI has role | CHEBI:37961 | H2 receptor antagonists |
CHEBI has role | CHEBI:49201 | anti-ulcer drugs |
CHEBI has role | CHEBI:50183 | P450 inhibitors |
CHEBI has role | CHEBI:60809 | adjuvants |
MeSH PA | D000897 | Anti-Ulcer Agents |
MeSH PA | D065609 | Cytochrome P-450 CYP1A2 Inhibitors |
MeSH PA | D065607 | Cytochrome P-450 Enzyme Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D005765 | Gastrointestinal Agents |
MeSH PA | D018494 | Histamine Agents |
MeSH PA | D006633 | Histamine Antagonists |
MeSH PA | D006635 | Histamine H2 Antagonists |
MeSH PA | D065606 | Metabolic Side Effects of Drugs and Substances |
MeSH PA | D018377 | Neurotransmitter Agents |
FDA EPC | N0000175784 | Histamine-2 Receptor Antagonist |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Heartburn | indication | 16331000 | |
Upper gastrointestinal hemorrhage | indication | 37372002 | |
Duodenal ulcer disease | indication | 51868009 | DOID:1724 |
Zollinger-Ellison syndrome | indication | 53132006 | DOID:0050782 |
Multiple endocrine adenomas | indication | 60549007 | |
Indigestion | indication | 162031009 | |
Gastroesophageal reflux disease | indication | 235595009 | DOID:8534 |
Systemic mast cell disease | indication | 397016004 | DOID:349 |
Gastric ulcer | indication | 397825006 | DOID:10808 |
Upper GI Bleed Prevention | indication | ||
Maintenance of Healing Duodenal Ulcer | indication | ||
Pancreatic insufficiency | off-label use | 37992001 | |
Urticaria | off-label use | 126485001 | |
Prevention of Stress Ulcer | off-label use | ||
NSAID-Induced Gastric Ulcer | off-label use | ||
Impaired renal function disorder | contraindication | 197663003 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Malignant tumor of stomach | contraindication | 363349007 | DOID:10534 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 13.83 | acidic |
pKa2 | 6.71 | Basic |
pKa3 | 0.0 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Histamine H2 receptor | GPCR | ANTAGONIST | Kd | 6.14 | WOMBAT-PK | CHEMBL | |||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 5.16 | PDSP | |||||
Multidrug and toxin extrusion protein 1 | Transporter | IC50 | 5.92 | CHEMBL | |||||
Multidrug and toxin extrusion protein 2 | Transporter | INHIBITOR | Ki | 5.10 | IUPHAR | ||||
Histamine H2 receptor | GPCR | Kd | 6.58 | CHEMBL | |||||
Histamine H2 receptor | GPCR | ANTAGONIST | Ki | 5.90 | IUPHAR |
ID | Source |
---|---|
4018845 | VUID |
N0000147147 | NUI |
D00295 | KEGG_DRUG |
70059-30-2 | SECONDARY_CAS_RN |
152402 | RXNORM |
4018844 | VANDF |
4018845 | VANDF |
C0008783 | UMLSCUI |
CHEBI:3699 | CHEBI |
CHEMBL30 | ChEMBL_ID |
CHEMBL1201051 | ChEMBL_ID |
DB00501 | DRUGBANK_ID |
D002927 | MESH_DESCRIPTOR_UI |
2756 | PUBCHEM_CID |
1231 | IUPHAR_LIGAND_ID |
3765 | INN_ID |
80061L1WGD | UNII |
101 | MMSL |
2261 | MMSL |
4448 | MMSL |
4449 | MMSL |
6098 | MMSL |
d00140 | MMSL |
003415 | NDDF |
004987 | NDDF |
373541007 | SNOMEDCT_US |
83051006 | SNOMEDCT_US |
83532008 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8192 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 20 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8192 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 20 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8204 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8204 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8305 | TABLET, FILM COATED | 800 mg | ORAL | ANDA | 20 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8305 | TABLET, FILM COATED | 800 mg | ORAL | ANDA | 20 sections |
Good Sense Heartburn Relief | HUMAN OTC DRUG LABEL | 1 | 0113-0022 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 16 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0649 | SOLUTION | 300 mg | ORAL | ANDA | 15 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0649 | SOLUTION | 300 mg | ORAL | ANDA | 15 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-1298 | SOLUTION | 400 mg | ORAL | ANDA | 15 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-1298 | SOLUTION | 400 mg | ORAL | ANDA | 15 sections |
cimetidineacid reducer | HUMAN OTC DRUG LABEL | 1 | 0363-0022 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 15 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0053 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 20 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0317 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 20 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0372 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0541 | TABLET, FILM COATED | 800 mg | ORAL | ANDA | 20 sections |
CIMETIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0440-1282 | TABLET | 400 mg | ORAL | ANDA | 15 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-626 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-627 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 20 sections |
CIMETIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-048 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 17 sections |
CIMETIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-265 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
CIMETIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-372 | TABLET, FILM COATED | 800 mg | ORAL | ANDA | 20 sections |
CIMETIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-531 | TABLET | 300 mg | ORAL | ANDA | 14 sections |
CIMETIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-532 | TABLET | 400 mg | ORAL | ANDA | 14 sections |
Good Neighbor Pharmacy Heartburn Relief | HUMAN OTC DRUG LABEL | 1 | 24385-111 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 16 sections |
Acid Reducer | HUMAN OTC DRUG LABEL | 1 | 30142-323 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 16 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-024 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-217 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 20 sections |
Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-218 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
Equate Cimetidine | HUMAN OTC DRUG LABEL | 1 | 49035-820 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 15 sections |